Crossmark

Tislelizumab plus anlotinib with or without radiotherapy as first-line therapy in advanced hepatocellular carcinoma: a single center, non-randomized retrospective case–control study

Crossref DOI link: https://doi.org/10.1007/s12672-025-02171-5

Published Online: 2025-03-25

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Wu, Guishu

Liu, Yuhong

Fan, Huaxi

Rao, Mingyue

Zhang, Jing

Zhang, Jianwen
License Information

Text and Data Mining valid from 2025-03-25

Version of Record valid from 2025-03-25
More Information

Article History

Received: 18 September 2024

Accepted: 18 March 2025

First Online: 25 March 2025

Declarations

:

: The study was approved by the Ethics Committee and Institutional Review Board of the Affiliated Hospital of Southwest Medical University (9/8/2020/KY2020135) and followed the ethical guidelines of the 1975 Declaration of Helsinki. Informed consent was obtained from all individual participants included in the study.

: The authors affirm that the human research participants provided informed consent for the publication.

: The authors have no relevant financial or non-financial interests to disclose.

Document is current

Any future updates will be listed below